Ortega FJM, Sáenz NJC, Posada MF, Velarde LM

Language: Spanish
References: 11
Page: 227-234
PDF size: 165.90 Kb.

ABSTRACT

Cervical cancer is the second cause of mortality from malignant neoplasms in women in our country. Objectives: To determine the prevalence of high-risk human papillomavirus (HPV) genotypes detected by polymerase chain reaction (PCR) in the state of Chihuahua. Material and methods: Observational, transversal, and ambispective. Women in the different regions of the state of Chihuahua between 35 and 64 years of age were screened, obtaining samples for HPV management to detect HPV-16 and HPV-18 genotypes and the high-risk HPV pool. Results: Samples were obtained from 53 municipalities of the State of Chihuahua, adding a total of 2523 samples. A prevalence of 19.5% was found, obtaining 59 cases with HPV-16, 26 with HPV-18, and 363 with a high-risk HPV pool. A positive correlation is shown for the three variables: early sexual initiation (< 18 years), history of multiple sexual partners, and smoking with the risk of having high-risk HPV infection with a relative risk of 1.37, 1.63, and 2.15 respectively. Conclusion: This study demonstrated the high prevalence of high-risk HPV genotypes in the population of the state of Chihuahua.

REFERENCES

1. Fajardo-Ramírez OR, Barboza-Cerda MC, Ortiz-López R, Rojas-Martínez A, Garza-Rodríguez ML, Sepúlveda-Flores A et al. Prevalence and 3-year persistence of human papillomavirus serotypes in asymptomatic patients in Northern Mexico. Int J Gynaecol Obstet. 2017; 136 (1): 40-46.

2. IARC Working group on the evaluation of carcinogenic risks to humans. Biological agents. Volume 100 B. A review of human carcinogens. IARC Monogr Eval Carcinog Risks Hum. 2012; 100 (Pt B): 1-441.

3. Anaya-Ruiz M, Vincent AK, Perez-Santos M. Cervical cancer trends in Mexico: incidence, mortality and research output. Asian Pac J Cancer Prev. 2014; 15 (20): 8689-8692.

4. Hernández-Hernández DM, Apresa-García T, Patlán-Pérez RM. Panorama epidemiológico del cáncer cervicouterino. Rev Med Inst Mex Seguro Soc. 2015; 53 (Suppl 2): S154-61.

5. Crosbie EJ, Einstein MH, Franceschi S, Kitchener HC. Human papillomavirus and cervical cancer. Lancet. 2013; 382 (9895): 889-899. Available in: http://dx.doi.org/10.1016/ S0140-6736(13)60022

6. Bonello K, Blundell R. The role of the human papillomavirus (HPV) in cervical cancer: a review about hpv-induced carcinogenesis and its epidemiology, diagnosis, management and prevention. Int J Med Students. 2016; 4 (1): 26-32.

7. Cárdenas Hernández JL, Escobedo García A, Gómez Villa EA, Hernández Pérez I, Juárez Ramiro A, Martínez Ordoñez A et al. Prevención y detección oportuna del cáncer cérvico uterino en el primer nivel de atención. Actualización 2011. México. Instituto Mexicano del Seguro Social, 2010.

8. Rincón RDF, Morales LLA, Rincón-Orozco B. Modernas metodologías diagnósticas para la detección del virus del papiloma humano y prevención del cáncer de cuello uterino. Salud UIS. 2017; 49 (3): 478-488.

9. Martínez-Portilla RJ, López-Velázquez JL, Martínez-Rojas GC, Aguilar Villagómez MI, De la Torre-Rendón FE, Villafán-Bernal JR. Prevalencia de serotipos de VPH de alto riesgo detectados por PCR en pacientes con citología normal del Hospital Regional Adolfo López Mateos, ISSSTE. Ginecol Obstet Mex. 2016; 84 (09): 556-561.

10. Romero-Morelos P, Uribe-Jiménez A, Bandala C, Poot-Vélez A, Ornelas-Corral N, Rodríguez-Esquivel M et al. Genotyping of the human papilloma virus in a group of mexican women treated in a highly specialist hospital: multiple infections and their potential transcendence in the current vaccination programme. Med Clin (Barc). 2017; 149 (7): 287-292.

11. Flores-Medina S, García-Romero CS, Soriano-Becerril DM, Figueroa-Damián R, Márquez-Acosta G. Genotipificación del virus del papiloma humano en mujeres que asisten a un hospital gineco-obstétrico de tercer nivel de la Ciudad de México. Rev Chil Obstet Ginecol. 2016; 81 (5): 381-387.